Drug profile · INN
dipivefrin hydrochloride
PROPINE
dipivefrin hydrochloride (PROPINE) is a adrenergic receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — dipivefrin hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
dipivefrin hydrochloride (PROPINE) is a adrenergic receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor agonist
Primary target: Adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dipivefrin hydrochloride?
dipivefrin hydrochloride (PROPINE) is a adrenergic receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for dipivefrin hydrochloride?
PROPINE is a marketed brand name for dipivefrin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dipivefrin hydrochloride?
dipivefrin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.